Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00088179|
Recruitment Status : Completed
First Posted : July 23, 2004
Last Update Posted : February 22, 2018
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Drug: pexelizumab in conjunction with CABG||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||4000 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)|
|Actual Study Start Date :||July 2004|
|Actual Primary Completion Date :||October 2005|
|Actual Study Completion Date :||October 2005|
- Reduction in mortality.
- Reduction in MI incidence.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00088179
Show 188 Study Locations
|Study Director:||Peter X Adams, MD||Alexion Pharmaceuticals|
|Study Chair:||Edward Verrier, MD||University of Washington|